As of November 6, 2017
FDA approves alectinib (Alecensa) as 1st line treatment based on Phase 3 results.
The estimated median Progression Free Survival (PFS) for patients taking alectinib was 25.7 months, compared with 10.4 months for those taking crizotinib.
The Objective Response Rate (ORR) was 79% and 72% in the alectinib and crizotinib arms, respectively.
Among the 120 responders in the alectinib arm and the 109 responders in the crizotinib arm, the proportion of patients with response duration of ≥12 months was 64% and 36%, respectively.
The Central Nervous System (CNS) ORR was 81% among patients taking alectinib and 50% among patients taking crizotinib.
Among patients with measurable CNS lesions and a CNS response, the proportion of patients with a CNS response duration of ≥12 months was 59% in the alectinib arm and 36% in the crizotinib arm.